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Abstract
Diagnostic histopathology of soft tissue tumors can be troublesome as many entities
are quite rare and have overlapping morphologic features. Many soft tissue tumors
harbor tumor-defining gene translocations, which may provide an important ancillary
tool for tumor diagnosis. The NanoString nCounter platform enables multiplex detec-
tion of pre-defined gene fusion transcripts in formalin-fixed and paraffin-embedded
tissue. A cohort of 104 soft tissue tumors representing 20 different histological types
was analyzed for the expression of 174 unique gene fusion transcripts. A tumor-
defining gene fusion transcript was detected in 60 cases (58%). Sensitivity and speci-
ficity of the NanoString assay calculated against the result of an alternative molecular
method were 85% and 100%, respectively. Highest diagnostic coverage was obtained
for Ewing sarcoma, synovial sarcoma, myxoid liposarcoma, alveolar rhabdomyosar-
coma, and desmoplastic small round cell tumor. For these tumor types, the
NanoString assay is a rapid, cost-effective, sensitive, and specific ancillary screening
tool for molecular diagnosis. For other sarcomas, additional molecular testing may be
required when a translocation transcript is not identified with the current 174 gene
fusion panel.
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1 | INTRODUCTION
Soft tissue tumors represent a remarkably heterogeneous group of
neoplasms, with many subtypes being exceptionally rare. More than
100 different soft tissue tumors have been described in the latest
2013 WHO classification.1 The proper histological classification of
soft tissue tumors is grounded in the microscopic analysis of tumor
growth patterns and their cytological features, which may be a diffi-
cult exercise, since many tumors have overlapping morphologic fea-
tures. Although tumor-associated protein markers may be visualized
by ancillary immunohistochemistry (IHC), many tumors show non-
specific, overlapping or absent marker expression. Thus, it may be
difficult or impossible to render an objective accurate diagnosis, in
particular when studying small biopsy specimens with a limited
amount of tumor tissue.
Fortunately, a significant number of soft tissue tumors, in par-
ticular those with monomorphic round cell, spindle cell or epitheli-
oid morphology, harbor recurrent gene translocations, which are
often tumor-specific. These unique recurrent translocations were
first discovered in the early 1990s by chromosomal banding tech-
niques, for example, the t(X;18)(p11;q11) translocation in synovial
sarcoma, which results in the tumor specific SS18-SSX fusion
genes.2 At the molecular level, with knowledge of the exon regions
involved in fusion genes, RT-PCR and Fluorescence In Situ
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Hybridisation (FISH, using break-apart probes) methods became
available to detect these particular gene fusions and rearrangements.
In the past decade, pathologists have witnessed the rapid develop-
ment of next generation sequencing (NGS) techniques, which allow
simultaneous detection of multiple fusion transcripts. This trans-
lated into more accurate classification and also prognostication of
soft tissue tumors.3 At present, the two novel molecular multiplex
methods commonly used in Dutch sarcoma centers are the
anchored multiplex PCR (AMP)-based NGS (Archer FusionPlex Sar-
coma assay)4 and the NanoString nCounter platform.5 The Archer
AMP PCR method targets exons of 26 genes commonly involved in
fusion genes of soft tissue tumors, whereas the NanoString assay
is a high-throughput hybridization technique, which uses specific
probes that target 174 unique gene fusion junctions in 22 soft tis-
sue tumor types.6
In this quality control study, we evaluated the sensitivity and
specificity of the NanoString nCounter platform for gene fusion
detection in 22 different soft tissue tumors, adding our results to the
initial report on this method.7
2 | MATERIALS AND METHODS
2.1 | Case selection
Case selection included 106 soft tissue tumors derived from the
archives of the Department of Pathology in the University Medical
Center Groningen and diagnosed between 1988 and 2018. The series
comprised 22 different translocation-associated tumor types. All cases
were reviewed by a pathologist with special expertise in diagnostic
pathology of soft tissue tumors (A.S.). In all cases, Formalin-Fixed and
Paraffin-embedded (FFPE) material was available, in the large majority
of cases from tumor excision or resection specimens. In two tumor
specimens (one undifferentiated round cell sarcoma and one
desmoplastic small round cell tumor), RNA quantity was too low to
allow proper analysis. Thus, 104 tumors were eventually included in
the study, of which 59 tumors had been tested previously by an alter-
native molecular method (Figure 1), including FISH (36 cases), RT-PCR
(12 cases), FISH and RT-PCR (7 cases), or Archer NGS (4 cases). Fifty-
two out of fifty-nine cases were fusion positive by alternative
F IGURE 1 Overview of Nanostring nCounter FusionPlex results [Color figure can be viewed at wileyonlinelibrary.com]
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molecular tests. In the remaining 45 cases, in which no molecular
methods had been applied, the tumor diagnosis was based on clinical
presentation and histologic features in combination with IHC.
The study was approved by the UMCG institutional ethical
review board (P18-116) and performed in accordance with the code
of conduct for responsible use of human tissue that is used in the
Netherlands (Dutch Federation of Biomedical Scientific Societies;
http://www.federa.org).
2.2 | NanoString gene expression profiling
RNA was isolated from four 5-μm-thick formalin-fixed and paraffin-
embedded tissue sections containing at least 50% tumor cells using
the RNeasy mini kit (Qiagen) according to suppliers instructions. Total
RNA was quantified with Qubit (ThermoFisher).
The soft tissue and bone tumor probe set as described by Chang
et al.7 was ordered from IDT Technologies (Leuven, Belgium). In con-
trast to the initial study, our panel did not contain probes for the
detection of COL1A1-PDGFB gene fusion transcripts, as can be found
in dermatofibrosarcoma protuberans. Probes were hybridized with
100 ng RNA overnight in a thermocycler at 67C with a heated-lid at
72C. The RNA-probe complexes were loaded on an nCounter car-
tridge, and hybridized, washed and read on a nCounter SPRINT plat-
form according to suppliers instructions (NanoString nCounter
Technologies, Seattle, WA).
2.3 | Data analysis
The platform-generated Reporter Code Count (RCC) files containing
the raw data were analyzed. Samples with a geometric mean of the
raw counts of the four reference genes (ACTB, GAPDH, SDHA, UBC) of
<500 were excluded from the analysis due to low RNA input or poor
RNA quality. Subsequent data normalization were performed with the
nSolver Analysis Software (NanoString nCounter Technologies) to cor-
rect for differences in hybridization efficiency using the respective con-
trol probes. Counts were not corrected for RNA input. Following a log2
transformation of the normalized data, the interquartile range (IQR) of
counts for each probe across all samples in the run was calculated. Out-
liers in each sample, that is, positive signal for a gene fusion transcript,
were determined as counts larger than 1.5*IQR, and which exceed the
background threshold of 40 counts. The counts were not compared to
the median of the counts across all the probes within a sample as
reported by Chang et al.7 A comparison of both methods did not alter
the results for the sample set described in this work (data not shown).
3 | RESULTS
As shown in Figure 1 and Table 1, the NanoString assay detected
gene fusions in 60/104 cases suitable for analysis. In 44/60
NanoString positive cases, a similar gene fusion had already been
detected by previous alternative molecular testing. In the other 16/60
cases, no previous molecular testing had been performed. The
detected fusion genes are summarized in Table S1.
In 44/104 cases, no fusion was detected by the NanoString assay,
whereas in 8/44 cases, a gene rearrangement or fusion had been
found by prior alternative molecular testing (5 by FISH, 2 by FISH and
RT-PCR, and 1 by targeted NGS). Thus, there were no false-positive
NanoString results and eight false-negative NanoString results. Over-
all, fusion gene detection by NanoString had a sensitivity of 85% and
specificity of 100%.
3.1 | Concordant and discordant (false-negative)
cases
Of the 52/104 cases, in which a gene rearrangement or fusion had
been detected by prior molecular testing, NanoString was positive
(concordant) in 44 cases and negative (discordant) in 8 cases. With
respect to soft tissue tumor type, concordant cases included all eight
Ewing sarcomas (four with EWSR1-FLI1, three with EWSR1-ERG, and
one with EWSR1-FEV), all eight synovial sarcomas with SS18-SSX1/2,
all seven myxoid liposarcomas with FUS/EWSR1-DDIT, and all three
desmoplastic small round cell tumors (DSRCT) with EWSR1-WT1.
Table 2 summarizes the eight discordant cases, in which
NanoString failed to detect gene fusions that were detected by other
molecular methods. These discordant cases included one single
BCOR-rearranged sarcoma (with a BCOR (exon 15)-CCNB3 (exon 5)
fusion gene detected by Archer) and one single CIC-rearranged sar-
coma (with CIC rearrangement detected by FISH). Moreover,
NanoString was negative in 1/4 clear-cell sarcomas (positive by FISH
EWSR1 break-apart assay), 2/5 epithelioid hemangioendotheliomas
(positive by FISH for WWTR1-CAMTA1), and 2/4 inflammatory myo-
fibroblastic tumors (one with ALK rearrangement by FISH and one
with EML4 (exon2)-ALK1 (exon20) by RT-PCR).
3.2 | Positive NanoString results in cases without
prior molecular testing
As shown in Table 1, 16 fusion-positive cases were detected by
NanoString, which had no previously molecular testing, including 2/3
alveolar soft part sarcomas, 3/5 alveolar rhabdomyosarcomas, 1/6
aneurysmal bone cysts, 1/5 angiomatoid fibrous histiocytomas, 3/6
mesenchymal chondrosarcomas, 2/7 myxoid liposarcomas, 3/5 cases
of nodular fasciitis, and 1/5 extraskeletal myxoid chondrosarcomas.
3.3 | The relative value of the NanoString assay is
strongly associated with the level of diagnostic
evidence in daily practice
In order to determine the usefulness of NanoString testing in daily
pathology practice, we divided the 104 soft tissue and bone (STB)
SONG ET AL. 3
tumors in three groups according to their level of diagnostic evidence,
as shown in Figure 2. Group 1 consisted of 52 STB tumors in which the
histological diagnosis was confirmed by prior alternative molecular test-
ing. Fusion genes transcripts were detected by NanoString in 44 cases
(85%). Group 2 consisted of 36 STB tumors in which the histological
diagnosis was based on typical histological features, often in combina-
tion with IHC findings. Fusion gene transcripts were detected by
NanoString in 15 cases (42%). Group 3 consisted of 16 STB tumors, in
which the histological diagnosis was uncertain, due to overlapping or
undifferentiated morphologic features and lack of specific IHC markers.
In this group, a fusion gene transcript was detected by NanoString in
only one case (6%), an extraskeletal myxoid chondrosarcoma with an
EWSR1-NR4A3 fusion.
3.4 | Estimated diagnostic coverage of NanoString
in STB tumors
By combining the results of this study (Table 1) with those obtained
by Chang et al.7 (as shown in their Table 2), it may be concluded that
the NanoString nCounter assay has an excellent diagnostic coverage
for five tumor types. In both studies, specific fusion genes were
detected in all cases of Ewing sarcoma (n = 28), synovial sarcoma

















Alveolar soft part sarcoma 3 — — 2 — — 1
Alveolar rhabdomyosarcoma 5 2 — 3 — — —
Aneurysmal bone cyst 6a 2 — 1 — — 3
Angiomatoid fibrous histiocytoma 5 3 — 1 — — 1
BCOR-rearranged sarcoma 1b — — — 1 — —
Biphenotypic sinonasal sarcoma 3 1 — — — — 2
CIC-rearranged sarcoma 1 — — — 1 — —
Clear-cell sarcoma 4 3 — — 1 — —
Congenital/infantile fibrosarcoma 3 2 — — — — 1
Desmoplastic small round cell tumor 3 3 — — — — —
Epithelioid hemangioendothelioma 5 2 — — 3 — —
Ewing sarcoma 8c 8 — — — — —
Undiff. round cell sarcoma 7 — — — — 5 2
Extraskeletal myxoid chondrosarcoma 5 2 — 1 — 1 1
Inflammatory myofibroblastic tumor 7 2 — — 2 — 3
Lipoblastoma 3 — — — — — 3
Mesenchymal chondrosarcoma 6 1 — 3 — — 2
Myoepithelial tumor 4 — — — — 1 3
Myxoid liposarcoma 7 5 — 2 — — —
Nodular fasciitis 5 — — 3 — — 2
Synovial sarcoma 8 8 — — — — —
Tenosynovial giant cell tumor 5 — — — — — 5
Total cases 104 44 0 16 8 7 29
aTwo soft tissue tumors, four bone tumors.
bA bone tumor.
cFour soft tissue tumors, four bone tumors.
TABLE 2 Summarize of eight discordant cases
Tumor
Case
(n) Alternative testing results
BCOR-rearranged sarcoma 1 NGS found BCOR (exon15)—
CCNB3 (exon 5)
CIC-rearranged sarcoma 1 FISH found CIC-DUX4







2 1 case RT-PCR found
EML4 (exon2)—ALK1
(exon20), 1 case FISH
found ALK positive
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(n = 19), myxoid liposarcoma (n = 12), alveolar rhabdomyosarcoma
(n = 10), and desmoplastic small round cell tumor (n = 5). Moreover,
five out of six infantile fibrosarcomas were diagnosed.
Tumors with an estimated diagnostic coverage of 50% to 75%
included nodular fasciitis (10/17), clear cell sarcoma (8/13), alveolar soft
part sarcoma (6/8), mesenchymal chondrosarcoma (6/8), angiomatoid
fibrous histiocytoma (5/7), extraskeletal myxoid chondrosarcoma (4/6),
and BCOR-rearranged sarcoma (3/4).
Tumors with a low diagnostic coverage of less than 50% included
epithelioid hemangioendothelioma (4/11), myoepithelial tumors (3/9),
aneurysmal bone cyst (3/9), inflammatory myofibroblastic tumor
(2/9), CIC-rearranged sarcoma (1/4), and biphenotypic sinonasal sar-
coma (1/3).
Tumors in which no fusion genes were detected included (CD99
negative) undifferentiated round cell sarcomas (13), tenosynovial giant
cell tumors (6), and lipoblastomas (4).
4 | DISCUSSION
Soft tissue tumors are highly heterogeneous in histological and molec-
ular subtypes. The identification of tumor type-specific gene translo-
cations has enabled a molecular classification with diagnostic and
prognostic value.8 In this study, we demonstrate that NanoString
fusion gene transcript profiling can reliably identify five molecularly
defined soft tissue tumors: Ewing sarcoma, synovial sarcoma, myxoid
liposarcoma, alveolar rhabdomyosarcoma, and desmoplastic small
round cell tumor. Further improvement of the assay can likely extend
its diagnostic value to other sarcoma subtypes.
The diagnostic coverage of the current design of the NanoString
panel for the other relatively rare tumor types included in this study is
limited. The most likely reason for this is the lack of probes for known
and unknown gene fusion events. Furthermore, lack of performance
was demonstrated for a few probes in the current design. The probe
for EML4 (exon2)-ALK (exon 20) did not identify this gene fusion
event in two inflammatory myofibroblastic tumors that were previ-
ously determined by RT-PCR and FISH. However, analysis of these
samples with the commercially available lung carcinoma fusion gene
panel did demonstrate this transcript in these tumors (data not
shown).
For other previously identified translocations that could not be
confirmed with the current NanoString panel, it is unknown whether
this is due to a lack of performance of the fusion gene probes or a lack
of probes for other known and unknown fusion. For example, this
study included one CIC-rearranged sarcoma in which a CIC
rearrangement was demonstrated by FISH previously. However, a
F IGURE 2 Diagnostic value of Nanostring nCounter FusionPlex in different fusion-associated tumor types. α: Two alveolar
rhabdomyosarcomas, two aneurysmal bone cysts, three angiomatoid fibrous histiocytomas, one biphenotypic sinonasal sarcoma, three clear cell
sarcomas, two infantile fibrosarcomas, three desmoplastic small round cell tumors, two epithelioid hemangioendotheliomas, eight Ewing
sarcomas, two extraskeletal myxoid chondrosarcomas, two inflammatory myofibroblastic tumors, one mesenchymal chondrosarcoma, five myxoid
liposarcomas, and eight synovial sarcomas. β: One BCOR-rearranged sarcoma, one CIC-rearranged sarcoma, one clear cell sarcoma, three
epithelioid hemangioendotheliomas, and two inflammatory myofibroblastic tumors. γ: Two alveolar soft part sarcomas, three alveolar
rhabdomyosarcomas, one aneurysmal bone cyst, one angiomatoid fibrous histiocytoma, three mesenchymal chondrosarcomas, two myxoid
liposarcomas, and three nodular fasciitis. δ: One alveolar soft part sarcoma, three aneurysmal bone cysts, one angiomatoid fibrous histiocytoma,
two biphenotypic sinonasal sarcomas, one infantile fibrosarcoma, one inflammatory myofibroblastic tumor, three lipoblastomas, two
mesenchymal chondrosarcomas, two nodular fasciitis, and five tenosynovial giant cell tumors. ε: One extraskeletal myxoid chondrosarcoma. ζ:
Seven undifferentiated round cell sarcomas, two extraskeletal myxoid chondrosarcomas, two inflammatory myofibroblastic tumors, and four
myoepithelial tumors [Color figure can be viewed at wileyonlinelibrary.com]
SONG ET AL. 5
CIC-DUX4 fusion gene transcript could not be detected. It is estimated
that CIC-DUX4 fusions can be observed in approximately 60% of CIC-
rearranged sarcomas, with lower incidence of others fusion partner
such as FOXO4 and NUTM1.9,10 Chang et al.7 demonstrated that the
current NanoString panel identified one CIC-DUX4 fusion transcript in
four CIC-rearranged sarcomas, indicating that at least one of the pro-
bes is working. Therefore, and in contrast to well-studied soft tissue
tumors such as Ewing sarcoma and synovial sarcoma, the current
panel design has a high false negative rate for rare tumors in which
the gene-fusion partners and exact location of the break are poorly
characterized. The combined analysis of the current and previously
published study7 indicates, with the exception Ewing sarcoma, syno-
vial sarcoma, myxoid liposarcoma, alveolar rhabdomyosarcoma, and
desmoplastic small round cell tumors, a moderate to high risk of a
false negative result (25% and higher, depending on tumor type).
The current panel appears not suitable for the molecular analysis
of undifferentiated round cell carcinoma, lipoblastoma, and ten-
osynovial giant-cell tumors. Despite the inclusion of probes for fusion
genes frequently detected in these tumors, none were positive in the
NanoString analysis.
In addition to the tumor type-specific performance of this
NanoString test, the percentage of tumor cells in a sample as well as
RNA quality can contribute to a false-negative test result. Although
the minimal percentage of tumor cells in a sample that is required
for a confident detection of a gene fusion transcript was not deter-
mined, only samples with >50% tumor cellularity were included. Fur-
thermore, only samples from which at least 15 ng RNA/μL could be
extracted were analyzed with NanoString using 100 ng RNA input.
Some samples were analyzed with 300 ng RNA input, but that did
not result in a higher diagnostic yield (data not shown). Despite a
high RNA yield from one desmoplastic small round cell tumor and
one undifferentiated round cell sarcoma, counts for the reference
genes were insufficient for analyses. Re-examination of both tissues
revealed extensive necrosis that was presumably causal to poor
RNA quality. Therefore, irrespective of sufficient tumor cellularity
and RNA yield, a NanoString analysis can fail due to poor RNA
quality.
The cost effectiveness and short turn-around time of a
NanoString analysis is a strong argument for the replacement of FISH
and RT-PCR as the initial screening test for sarcomas.5 Turnaround
time for FISH and a NanoString assay in a diagnostic setting is compa-
rable, yet a NanoString assay is less labor intensive. In agreement with
Chang et al.,7 the cost per sample of a FISH analysis (one target-one
sample) is comparable to one multiplex NanoString analysis when ana-
lyzing 12 samples simultaneously. NanoString thus significantly
reduces the cost per sample while maintaining a short turnaround
time. However, when no fusion event is identified, additional molecu-
lar profiling based on, for example, multiplex PCR (AMP)-based NGS
may be necessary. This will be required for those tumors for which
the current NanoString panel has a low diagnostic yield. For these
tumor types, analysis Archer RNA-seq NGS is likely more effective,11
but is associated with higher costs and longer turnaround times that
are comparable to NGS sequencing of large targeted panels.
In conclusion, the NanoString nCounter FusionPlex assay is a
screening tool with high sensitivity and specificity5-7,12,13 for the
detection of sarcoma-defining fusion gene transcripts in Ewing sar-
coma, synovial sarcoma, myxoid liposarcoma, alveolar rhabdomyosar-
coma, and desmoplastic small round cell tumors. Its diagnostic yield
for rare soft tissue tumors is limited and might require additional or
alternative testing.
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